Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-Related Deaths Marking These As Ninth Leading Cause Of Death In U.S.
Portfolio Pulse from Benzinga Newsdesk
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc. (NYSE:BHC), has released its third Liver Health Trends Report, which shows a 9% increase in chronic liver disease (CLD) and cirrhosis mortality in the US in 2021. The report also highlights ongoing disparities in CLD care, including a shortage of liver specialists in rural areas. The report is based on a survey of 400 health care providers, qualitative interviews, and secondary research from peer-reviewed publications.

October 10, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The report by Salix Pharmaceuticals, a subsidiary of Bausch Health Companies, could potentially raise awareness about chronic liver disease and the company's role in providing solutions. This could potentially lead to increased demand for their products and services.
The report highlights the increasing prevalence of chronic liver disease and the need for effective treatments. As a company providing solutions in this area, Bausch Health could potentially benefit from increased demand for their products and services. However, the actual impact will depend on various factors including the company's ability to meet this demand and the competitive landscape.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100